English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResearchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%.
Tag: HPV
Promise and Perils of Primary HPV Testing
Abstract Cervical cancer screening has reduced morbidity and mortality in many countries, but efforts to optimize screening modalities and schedules are ongoing. Using data from a randomized trial conducted in British Columbia, Canada, in conjunction with a provincial screening registry,…
Accurate sexual health information on TikTok? It’s this UCLA doctor’s mission
UCLA Health’s Dr. Russell Johnson educates and empowers on TikTok with accurate sexual health information Dr. Russell Johnson, UCLA Health primary care physician and HIV and sexual health expert, is available for interview on the following topics: Intersection of medicine,…
Improving access to HPV testing
Initiative aims to raise awareness of a cancer-causing virus
UChicago Medicine cancer experts available for interviews during ASCO
More than 40,000 oncology professionals from around the world are gathering in Chicago for The American Society of Clinical Oncology (ASCO) annual meeting, May 31–June 4, 2024. Cancer experts from the University of Chicago Medicine Comprehensive Cancer Center will present…
New B.C. Self-Screening Program Will Improve Accessibility of Cervical Cancer Testing
The launch of British Columbia’s province-wide program offering the first-ever option to self-screen for HPV in Canada will enhance access to cervical cancer screening for women and individuals with a cervix. Offering a more convenient, accessible way to screen for…
New Test Shows Promise for Detecting Hard-to-Find Cervical Cancers
In findings with potentially important implications for cervical cancer screening, scientists at the National Cancer Institute (NCI)-designated Montefiore Einstein Cancer Center (MECC) have developed a test for detecting a type of cervical cancer that Pap tests often miss. The findings published online today in the Journal of the National Cancer Institute (JNCI).
HPV Self-Collection Kits Increase Screening Among Under-screened, Under-served Women in North Carolina
Five years ago, the World Health Organization (WHO) announced a global call to eliminate cervical cancer. Because nearly all cervical cancers are caused by an initial infection with oncogenic types of human papillomavirus (HPV), screening for the virus is critical to preventing and treating the disease.However, providing HPV screening only within clinical settings may limit access to screening for many under-served women across the United States and here, in North Carolina.
New AACC Guidance Aims to Serve as a Roadmap for Healthcare Professionals Navigating Cervical Cancer Testing Options
With the goal of improving cervical cancer care, AACC has published a new guidance document with expert recommendations on detecting this cancer. The guidance aims to update healthcare and laboratory medicine professionals on the latest advancements in this field, and to help them select the most effective cervical cancer detection strategy for their patients.
MD Anderson Research Highlights for February 22, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a new understanding of how HPV drives cancer development, a combination therapy to overcome treatment resistance in mantle cell lymphoma, novel insights into memory T cell formation and potential therapeutic strategies for brain cancers, improved survival outcomes for metastatic colorectal cancer, targeting myeloperoxidase to improve immunotherapy responses in melanoma, and preclinical results of a combination therapy that could effectively treat a subset of acute myeloid leukemia.
Saint Louis University Researcher Receives $2.83 Million NIH Grant to Increase HPV Prevention Strategies in Nigeria
When designing strategies to create lasting impact in a particular community, there is no better resource than the strength and intelligence of the community members themselves, and in this case, girls and women. Using crowdsourcing as a framework, a Saint Louis University researcher aims to increase HPV vaccination and HPV screening to lower incidents of cervical cancer among girls and women in Nigeria.
Moffitt Cancer Center Joins Weill Cornell Medicine and University of North Carolina to Improve HIV-Related Cancer Care Abroad
Moffitt Cancer Center, Weill Cornell Medicine and the University of North Carolina School of Medicine have received a $3.5 million, five-year grant from the National Cancer Institute (NCI) to improve screening and preventative treatment of cervical cancer for women living with HIV in low-resource countries.
American Cancer Society Releases Latest Cancer Statistics, Launches Initiative to Address Prostate Cancer Resurgence and Disparities
Today, the American Cancer Society released Cancer Statistics, 2023, the organization’s annual report on cancer facts and trends. According to the report, overall cancer mortality has dropped 33% since 1991, averting an estimated 3.8 million cancer deaths. Based on ACS data, in 2023 there are projected to be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States.
CDC Data Suggests Attitudes Are Shifting about the HPV Vaccine: Utah Vaccine Rates among Teens Increased More than 16%
Many more Utah teens are getting vaccinated for HPV, protecting them against six types of cancer. The state saw a significant increase in HPV vaccinations after a long history of mixed messages and misunderstandings about the vaccine. Huntsman Cancer Institute experts explain what’s working, and one woman tells about her harrowing cancer journey.
Molecular Musical Chairs
The human papillomavirus (HPV) vaccine is safe and effective – but it’s not for everyone. Michelle Ozbun, PhD, and her team at UNM Cancer Center published a research article earlier this year in Antimicrobial Agents and Chemotherapy in which they describe how a drug called protamine sulfate blocks HPV infection. Like a game of musical chairs among molecules, the drug molecules bind to heparan sulfate cell receptors, preventing HPV virus particles from doing so.
MD Anderson Research Highlights for August 24, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include confirmation of improving response rates in Phase I trials over the last 20 years, a novel targeted therapy combination and biomarkers of response for chimeric antigen receptor (CAR) T cell therapy in B-cell lymphomas, a combination therapy for patients with melanoma brain metastases, and new treatment options for metastatic sarcomas, HPV-driven cancers and uterine cancer.
Expert Comment on Palliative Care for Cancer
New Brunswick, N.J., August 1, 2022 – Palliative care is a subspecialty of medicine that focuses on the comprehensive treatment of pain and symptoms accompanying many serious illnesses, including cancer. In cancer settings, palliative care helps patients do their best,…
Expert Available for Comment on Importance of HPV (human papillomavirus) Vaccine
New Brunswick, N.J., August 1, 2022 –The Centers for Disease Control and Prevention (CDC) estimates that persistent infection with the human papillomavirus (HPV) is responsible for more than 90 percent of anal and cervical cancers, about 70 percent of vaginal and vulvar…
Black and Hispanic Men with Throat Cancer Experiencing Higher Death Rates; White Men Increasingly Being Diagnosed at a Late Stage
Hispanic and Black men are dying from HPV-associated throat cancer at a higher rate, and most new cases are being diagnosed in white men at late-stage when it’s more difficult to treat, according to a new Rutgers study.
Mathematical Model Helps Predict Anal Cancer Risk in Persons with HIV Infection
UC San Diego researchers have created a mathematical model to help predict risk of anal cancer in persons with HIV infection and aid patients and doctors regarding screening decisions.
Mayo Clinic researchers find new treatment for HPV-associated oral cancer
Mayo Clinic researchers have found that a new, shorter treatment for patients with HPV-associated oropharynx cancer leads to excellent disease control and fewer side effects, compared to standard treatment.
The new treatment employs minimally invasive surgery and half the standard dose of radiation therapy, compared to current treatments. The new treatment also lasts for two weeks, rather than the standard six weeks.
Tennessee health care and public health leaders urge immediate action to protect state’s children from vaccine-preventable diseases
Tennessee health care providers, public health professionals and community stakeholders today issued an urgent call to action to protect Tennessee children from vaccine-preventable diseases.
Blood test shows promise for predicting treatment response in metastatic HPV-positive throat cancer
A new blood test could signal whether treatment for metastatic HPV-positive throat cancer is working months earlier than standard imaging scans, allowing doctors to try alternatives sooner, initial results show.
New Patient Guide from NCCN Jumpstarts Important Conversations About Anal Cancer
New and updated patient and caregiver resources from National Comprehensive Cancer Network (NCCN) offer jargon-free, state-of-the-art information on diagnosis, treatment, and surveillance for anal, colon, and rectal cancers.
Sanford Burnham Prebys and other top U.S. cancer centers call for urgent action to get cancer-preventing HPV vaccination back on track
Sanford Burnham Prebys has joined doctors & scientists across America at National Cancer Institute (NCI)-designated cancer centers & other organizations to issue a joint statement urging the nation’s physicians, parents & young adults to get the human papillomavirus (HPV) vaccination back on track.
Top Cancer Centers Call for Urgent Action to Get Cancer-Preventing HPV Vaccination Back on Track
As part of a unanimous effort on the part of the nation’s 71 National Cancer Institute (NCI)-designated cancer centers, Roswell Park Comprehensive Cancer Center is urging the nation’s physicians, parents and young adults to get cancer-preventing human papillomavirus (HPV) vaccination back on track.
Mayo Clinic Cancer Center joins national call to get HPV vaccinations back on track
Mayo Clinic Cancer Center has joined 71 National Cancer Institute-designated comprehensive cancer centers in calling on the nation’s health care providers, parents and young adults to help get HPV vaccinations back on track. HPV causes several types of cancers, and nearly everyone gets infected with HPV by age 50.
NCI-designated cancer centers call for urgent action to get cancer-preventing HPV vaccination back on track
The COVID-19 pandemic has interrupted delivery of key health services
for children and adolescents, including HPV vaccination for cancer prevention.
Cervical Cancer Testing Tech Could Replace Pap Smears, Save Lives
Emerging technologies can screen for cervical cancer better than Pap smears and, if widely used, could save lives in areas where access to health care may be limited. In Biophysics Reviews, scientists at Massachusetts General Hospital write advances in nanotechnology and computer learning are among the technologies helping develop HPV screening that take the guesswork out of the precancer tests. That could mean better screening in places that lack highly trained doctors and advanced laboratories.
St. Jude launches program to boost HPV cancer prevention across the globe
St. Jude is dedicating staff and resources to focus on the prevention of human papillomavirus (HPV)-related cancers around the world through HPV vaccine awareness programming.
A World without Cervical Cancer: Preventive Medicine publishes special issue to further global efforts to eliminate deadly disease
Cervical cancer is a serious global health threat which kills more than 300,000 women every year. Recognizing this urgent public health issue, the editorial team of Preventive Medicine is publishing a special issue titled “From Science to Action to Impact: Eliminating Cervical Cancer,” which outlines the required courses of action to eliminate cervical cancer. Dr. Anna Giuliano and Dr. Linda Niccolai, two giants in the field of cervical cancer prevention research, served as guest editors for the issue.
A Measure of Cleanliness
Michelle Ozbun, PhD, and her team developed a way to measure how many infectious human papillomavirus particles are left on a surface after it has been disinfected. They found that disinfectants approved for use on medical devices work well, and they recently published their work online in The Lancet journal EBioMedicine.
Behaviors Surrounding Oral Sex May Increase HPV-Related Cancer Risk
A wide breadth of behaviors surrounding oral sex may affect the risk of oral HPV infection and of a virus-associated head and neck cancer that can be spread through this route, a new study led by researchers at the Johns Hopkins Kimmel Cancer Center suggests. These findings add nuance to the connection between oral sex and oropharyngeal cancer — tumors that occur in the mouth and throat — and could help inform research and public health efforts aimed at preventing this disease.
Increasing HPV Vaccine Uptake in Adolescents
More than 90 percent of human papillomavirus (HPV)-related cancers could be prevented by widespread uptake of the HPV vaccine. Yet, vaccine use in the United States falls short of public health goals.
Albert Einstein College of Medicine Researchers Receive $5 Million NIH Grant to Study HIV and HPV Cancers in Africa
A team of scientists from Albert Einstein College of Medicine has received a five-year, $4.9 million grant from the National Institutes of Health (NIH) to establish a research center to investigate HIV- and human papillomavirus (HPV)-related cancers in Africa.
‘Pinprick’ biomarker blood test offers diagnostic potential for HPV-related cancers – clinical study shows rising antibody levels predict the course of cancer
A potential breakthrough in the early detection of the neck, head and anal cancers linked to human papilloma viruses (HPV) has emerged. It is based on a highly specific diagnostic test that appears to indicate cancer, and predict its course, from just a pinprick of blood.
$111 Million NIH Grant Awarded to Prevent and Treat HIV-Associated Cancers
The widespread use of antiretroviral therapy to suppress the HIV virus has helped tens of millions of people with HIV live healthier, longer lives—but an unfortunate consequence of people living longer with HIV is an increased risk of cancer. For 25 years, the AIDS Malignancy Consortium (AMC) has led national and international efforts to prevent and treat of HIV-related cancers. Now, Montefiore Health System and Albert Einstein College of Medicine have received a five-year, $111 million grant from the National Cancer Institute (NCI) to lead this research consortium.
HPV Vaccinations During Global Pandemic
Human papillomavirus (HPV) is the most common sexually transmitted infection and the cause of most cervical cancers, and some vaginal, penile, anal and oral cancers. The HPV vaccine has proven effective in preventing infection and six types of HPV-attributable cancers. …
10 Things to Know About HPV and Throat Cancer
As we observe World Head and Neck Cancer Day 2020 (July 27), nationally known expert Tom Thomas, MD, MPH, has set out to clear up misunderstandings about how one type of head and neck cancer is related to human papillomavirus (HPV), which has historically been thought of primarily as a cause of cervical cancer. Dr. Thomas is medical director, Head and Neck Reconstructive Surgery and Transoral Robotic Surgery, Leonard B. Kahn Head and Neck Cancer Institute at Atlantic Health System’s Morristown Medical Center and Carol G. Simon Cancer Center. He is one of the leaders of the Atlantic HPV Center.
Heather Brandt, Ph.D., to lead cancer prevention community outreach projects for St. Jude
Behavioral scientist will lead St. Jude community outreach and research programs focused on the prevention of HPV-associated cancers through vaccination
School HPV vaccine policies could result in higher vaccination rates, reduction in cancers
A UCLA-led study has found that in 2 of 3 states and jurisdictions with policies that require students entering school to receive the human papillomavirus vaccine, vaccination rates among 13-to-17-year-olds were significantly higher than in surrounding states without such policies.
Combining HPV vaccination with screening to prevent cervical cancer
While the latest findings on long-term efficacy of the HPV vaccine are cause for celebration, vaccinations should be coupled with preventive screening to better protect women from cervical cancer, two University of Michigan experts argue in an invited commentary in The Lancet’s EClinicalMedicine journal.
Cervical precancer identified by fluorescence, in a step toward bedside detection
Researchers developed a method using fluorescence to detect precancerous metabolic and physical changes in individual epithelial cells lining the cervix. The method, which can detect precancerous lesions non-invasively and non-destructively, opens the door to early-stage bedside diagnostics.
Young Men Unaware of Risks of HPV Infection and Need for HPV Vaccination
Young sexual minority men — including those who are gay, bisexual, queer or straight-identified men who have sex with men — do not fully understand their risk for human papillomavirus (HPV) due to a lack of information from health care providers, according to Rutgers researchers.
Cervical Cancer Screening Saves Lives
Cervical cancer is the third most common cancer in women worldwide, but most American women can prevent it by being screened on time with tests that detect human papillomaviruses (HPV). A new study led UNM Comprehensive Cancer Center scientists shows that screening every three years instead of annually prevents most cervical cancers.
Gaps in Cure Rate Appear Linked to Race and Insurance Status for a Common HPV-Related Cancer, According to New Research
Largest population-based analysis on factors that affect survival outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) find significant racial and socioeconomic disparities, according to new study in JNCCN-Journal of the National Comprehensive Cancer Network.
Vanderbilt-Ingram Cancer Center Patient First for New Cell Engineering Platform
VICC is the first cancer center to enroll a patient in a clinical trial for this new technology developed by SQZ Biotechnologies of Watertown, Massachusetts. The investigational product is generated from the company’s technology that uses high-speed cell deformation to squeeze cells, creating a temporary disruption of their membranes and offering a window for the insertion of tumor antigens.
The HPV vaccine: What parents need to know
The HPV vaccine protects against some of the deadliest, most disfiguring and hard-to-treat cancers. Here is what parents of teens and pre-teens should know about the HPV vaccine.
How Marijuana Accelerates Growth of HPV-related Head and Neck Cancer Identified
University of California San Diego School of Medicine researchers identified how THC from marijuana accelerates cancer growth in patients with human papillomavirus (HPV)-positive head and neck cancer.
Anal cancer rates and mortality have risen dramatically among Americans
Rates of new anal cancer diagnoses and deaths related to human papillomavirus (HPV), the most common sexually transmitted infection, have increased dramatically over the last 15 years, according to researchers at The University of Texas Health Science Center at Houston (UTHealth). The results of their study will be published in the November issue of the Journal of the National Cancer Institute.